Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15731924rdf:typepubmed:Citationlld:pubmed
pubmed-article:15731924lifeskim:mentionsumls-concept:C0682523lld:lifeskim
pubmed-article:15731924lifeskim:mentionsumls-concept:C0014084lld:lifeskim
pubmed-article:15731924lifeskim:mentionsumls-concept:C1335938lld:lifeskim
pubmed-article:15731924lifeskim:mentionsumls-concept:C1441547lld:lifeskim
pubmed-article:15731924lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:15731924lifeskim:mentionsumls-concept:C0205355lld:lifeskim
pubmed-article:15731924pubmed:issue3lld:pubmed
pubmed-article:15731924pubmed:dateCreated2005-3-25lld:pubmed
pubmed-article:15731924pubmed:abstractTextThe permanent human cell line C3842 was established from a secondary chondrosarcoma in a typical case of Ollier's disease. In the present study, we analyzed the morphological, cytogenetic and molecular biological characteristics of the cultured cells in comparison with the original tumor and investigated the invasion properties of the tumor model using functional imaging of proteolysis, matrigel assay and chick chorioallantoic membrane assay. C3842 cells exhibit the typical features of malignant cartilage tumor cells in vitro, including the expression of collagen types II, IX, XI and aggrecan. The proteolytic ability of C3842 cells is attributed to the expression of several proteases, such as cathepsin B, urokinase plasminogen activator and matrix-metalloproteinase-2, which enable the cells to degrade collagen type I and to permeate matrigel matrix. In accordance with the biological features in vivo, C3842 cells are not able to invade through the epithelium of the chick chorioallantoic membrane. In conclusion, the cell line C3842 provides the first model of a secondary chondrosarcoma in Ollier's disease in vitro, which is characterized by distinct features of such malignant cartilage tumors.lld:pubmed
pubmed-article:15731924pubmed:languageenglld:pubmed
pubmed-article:15731924pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15731924pubmed:citationSubsetIMlld:pubmed
pubmed-article:15731924pubmed:statusMEDLINElld:pubmed
pubmed-article:15731924pubmed:monthMarlld:pubmed
pubmed-article:15731924pubmed:issn0945-6317lld:pubmed
pubmed-article:15731924pubmed:authorpubmed-author:RoessnerAlber...lld:pubmed
pubmed-article:15731924pubmed:authorpubmed-author:DombrowskiFra...lld:pubmed
pubmed-article:15731924pubmed:authorpubmed-author:WieackerPeter...lld:pubmed
pubmed-article:15731924pubmed:authorpubmed-author:Schneider-Sto...lld:pubmed
pubmed-article:15731924pubmed:authorpubmed-author:HartigRolandRlld:pubmed
pubmed-article:15731924pubmed:authorpubmed-author:KalinskiThoma...lld:pubmed
pubmed-article:15731924pubmed:authorpubmed-author:KruegerSabine...lld:pubmed
pubmed-article:15731924pubmed:authorpubmed-author:PelzAntje-Fri...lld:pubmed
pubmed-article:15731924pubmed:authorpubmed-author:RöpkeMartinMlld:pubmed
pubmed-article:15731924pubmed:issnTypePrintlld:pubmed
pubmed-article:15731924pubmed:volume446lld:pubmed
pubmed-article:15731924pubmed:ownerNLMlld:pubmed
pubmed-article:15731924pubmed:authorsCompleteYlld:pubmed
pubmed-article:15731924pubmed:pagination287-99lld:pubmed
pubmed-article:15731924pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:meshHeadingpubmed-meshheading:15731924...lld:pubmed
pubmed-article:15731924pubmed:year2005lld:pubmed
pubmed-article:15731924pubmed:articleTitleEstablishment and characterization of the permanent human cell line C3842 derived from a secondary chondrosarcoma in Ollier's disease.lld:pubmed
pubmed-article:15731924pubmed:affiliationDepartment of Pathology, Otto-von-Guericke-University, Leipziger Strasse 44, 39120 Magdeburg, Germany. kalinski@medizin.uni-magdeburg.delld:pubmed
pubmed-article:15731924pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15731924pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15731924pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15731924lld:pubmed